To improve diagnosis and therapy for aplastic anaemia (AA) in Shanghai, clinical and laboratory data for patients with AA (n = 142) and hypocellular myelodysplastic syndrome (MDS; n = 22) were comparatively analysed (follow-up 2 -6 years). Red blood cell distribution width and absolute lymphocyte and reticulocyte counts were significantly different between the two groups. AA was diagnosed in 54.2% of patients using a single bone marrow aspirate smear plus peripheral haemogram results, and in 95.1% using an additional bone marrow biopsy; 4.9% required multiple-site bone marrow examination. Clonal chromosomal abnormalities occurred in 3.9% and 31.8% of patients with AA and MDS, respectively. In patients with severe AA, 12.0% received antithymocyte globulin (ATG) + cyclosporin A (CSA; effectiveness rate 77.8%; 5-year survival 74.1%), 45.3% received CSA + androgen therapy (effectiveness rate 58.8%; 5-year survival 76.5%) and 26.7% received androgen monotherapy (effectiveness rate 25.0%). Multivariate analysis of prognostic factors indicated that therapy regimen and blood platelet count affected survival. Peripheral blood smears, bone marrow spicule classification and biopsy are important diagnostic factors. Standardization of evidence-based therapy and promotion of ATG + CSA would improve general therapeutic effects in AA.
Introduction
Acquired aplastic anaemia (AA) is a rare haematological disease. The reported incidence of AA in American and European countries is around 0.23 per 100 000 population, per year. 1 -3 The incidence rate in Asia is 0.39 -0.5 per 100 000, 4, 5 which is approximately two-to three-fold higher. 6 A nationwide survey carried out in China during 1986 to 1988 indicated that the incidence of AA was 0.74 per 100 000, per year. 7 Aplastic anaemia is a syndrome that has many aetiological factors. It is essentially a failure in bone marrow haematopoiesis, without the infiltration of malignant cells or hyperplasia of reticulin fibres in the bone marrow. Many factors (such as physical or chemical exposure, 8 drug use and viral W Wang, X Wang, X Xu et al. Diagnosis and treatment of acquired aplastic anaemia infection) are related to the pathogenesis of this disease. 9 Immunological mechanisms are currently considered to be closely related to AA pathogenesis. 10, 11 Constitutional AA is caused by immune-mediated haematopoiesis failure. 12 In clinical practice, it is not difficult to diagnose typical AA. Atypical AA is, however, subject to misdiagnosis, especially when confusion arises between AA and hypocellular myelodysplastic syndrome (MDS): both diseases have overlapping clinical manifestations that are hard to distinguish from one another and can lead to misdiagnosis. 13 Aplastic anaemia can be classified as severe AA (SAA) or non-severe AA (NSAA), each having differing treatment strategies. At present, clinical practice guidelines are available to aid therapeutic decision making. 14 Before immunosuppressants were widely used, SAA was associated with a high mortality rate, with most patients dying of haemorrhage and infection. With the use of immunosuppressants, the therapeutic effects on SAA have been greatly improved. The effective rate for antithymocyte globulin (ATG) in combination with cyclosporin A (CSA) has reached over 60%, 15 with an 11-year survival rate of 58%. 16 There are also similar reports for China. For instance, excellent therapeutic effects have been achieved in Tianjin, 17 but no similar therapeutic results have been reported for Shanghai.
The present study sought to address issues involved in the diagnosis of acquired AA in adults, in order to improve the accuracy of its clinical diagnosis and treatment. This study also aimed to summarize the clinical data and laboratory test results for patients diagnosed with AA, and assess the effects of currently available therapies administered for AA in Shanghai, using indicators such as the effective and survival rates. 
Patients and methods PATIENTS

DIAGNOSTIC METHODS AND CRITERIA
All cases were subjected to a comprehensive series of standard diagnostic examinations, which included peripheral blood smears, bone marrow aspirate smears, cell morphology examinations, various cytochemical staining methods (including iron staining), cytogenetic studies (including chromosome G banding and fluorescence in situ hybridization [FISH]), flow cytometry and bone marrow pathology. The examinations were first performed individually by experts on cell morphology or bone marrow pathology. The final diagnosis was then made by clinical haematologists (X.W. and G.L.), and was based on a comprehensive evaluation of all examinations. If the first bone marrow aspiration was diluted, then diagnosis was made on this and a second bone marrow aspiration and biopsy. If the diagnosis was still uncertain, follow-up bone marrow aspirations and biopsies were performed at other sites. Diagnosis and classification of AA was made according to W Wang, X Wang, X Xu et al. Diagnosis and treatment of acquired aplastic anaemia the standard published by Camitta et al. in 1979 . 18 A diagnosis of AA was then further classified as either SAA or NSAA. The diagnosis of MDS was made according to the World Health Organization (WHO) standard for MDS diagnosis and classification. 19 The diagnosis of hypocellular MDS was based on bone marrow cellularity in the biopsy, which was < 30% for patients aged < 60 years and < 20% for patients ≥ 60 years. 20
THERAPEUTIC REGIMEN
The therapeutic regimen was divided into four groups: (i) ATG + CSA therapy (with or without androgen therapy or traditional Chinese medicine); (ii) CSA + androgen therapy (with or without traditional Chinese medicine); (iii) androgen monotherapy (with or without traditional Chinese medicine); and (iv) supportive therapy or traditional Chinese medicine. Porcine ATG was used at the standard dosage of 20 -30 mg/kg per day for 5 days. CSA was administered at 3 -5 mg/kg per day. Stanozolol (2 -4 mg, three times per day) or testosterone undecanoate (40 -80 mg, three times per day) were used for androgen monotherapy. Red blood cell transfusion was given if the haemoglobin level was < 60 g/l and platelet transfusion was given if they were < 20 × 10 9 /l. The Chinese medicine that was administered was complex including, for example, herbs that might improve red blood cell count, such as Angelica, Astragalus, dried longan, gelatin (glue from donkey skin), liquorice root and Achyranthes. No patient received an allogeneic transplantation. 
CASE FOLLOW-UP
THERAPEUTIC EFFECT STANDARD
According to the current consensus guidelines of the Serious Aplastic Anaemia Working Party of the European Group for Blood and Marrow Transplantation, 16 effective therapy includes complete remission (CR) and partial remission (PR). CR was defined as returning the peripheral haemogram back to normal, i.e. haemoglobin (Hb) levels ≥ 110 g/l, neutrophil counts ≥ 1.5 × 10 9 /l and platelet counts ≥ 100 × 10 9 /l. PR was defined as transfusion independence and failure to meet the criteria for SAA, with at least a 30 g/l increase in Hb levels, at least a 0.5 × 10 9 /l increase in neutrophil counts and at least a 20 × 10 9 /l increase in platelet counts over baseline values, or at least one cell line returning to normal or doubling. CR and PR were assessed 6 months after treatment.
STATISTICAL ANALYSES
Statistical evaluation of the data was carried out using STATA ® software, version 7.0 (StataCorp LP, College Station, Texas, USA) for Windows ® . Continuous variables were analysed using a Student's t-test and categorical variables using the χ 2 -test. Survival rates were calculated and survival curves plotted using the Kaplan-Meier method. The Cox proportional hazards model was used for multivariate analysis of the prognostic factors that affect survival. Survival time was defined as the period of time from diagnosis to death or the last follow-up. The patients who did not have follow-up were processed as censored data. A P-value of < 0.05 was considered to be statistically significant. W Wang, X Wang, X Xu et al.
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Results
GENERAL CLINICAL INFORMATION
The diagnostic criteria for AA were met in 142 cases. During the same period of time, 22 cases of hypocellular MDS were diagnosed and these formed the control cohort. Among the 142 cases of AA (77 males and 65 females), there were 75/142 (52.8%) cases of SAA (including two cases of very severe AA) and 67/142 (47.2%) cases of NSAA. The age of patients ranged from 18 to 82 years, with a median age of 35 years: 80/142 (56.3%) patients were aged ≤ 40 years and 23/142 (16.2%) patients were aged ≥ 60 years. Among the 22 cases of hypocellular MDS (13 males and nine females), there were 21 cases of refractory cytopaenia with multilineage dysplasia, and one case of refractory anaemia. The age of patients ranged from 19 to 83 years, with a median age of 57 years: 3/22 (13.6%) patients were aged ≤ 40 years and 11/22 (50.0%) were aged ≥ 60 years.
PERIPHERAL HAEMOGRAM AND BLOOD SMEAR EXAMINATIONS
Haemogram results are presented in Table 1 .
The SAA group had a significantly higher lymphocyte percentage and a lower mean corpuscular volume (MCV) than the NSAA and hypocellular MDS groups (both comparisons P < 0.01). The proportions of patients with MCV > 100 fl were 20.0% in the SAA group, 73.1% in the NSAA group and 54.5% in the MDS group. There was no significant difference in red blood cell distribution width (RDW) between the SAA group and the NSAA group. RDW in the hypocellular MDS group was significantly higher than in the AA groups (P < 0.05). Neither myeloblasts nor erythroblasts were seen in peripheral blood smears taken from patients with SAA. Only one case of NSAA showed 1% eosinophilic erythroblasts, but without myeloblasts, in peripheral blood smears. In hypocellular MDS cases, 18/22 (81.8%) showed myeloblasts or erythroblasts in peripheral blood smears.
BONE MARROW EXAMINATIONS
The results of bone marrow aspirations are presented in Table 2 . Dilution of the first bone marrow aspirate occurred in 18/142 (12.7%) W Wang, X Wang, X Xu et al.
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showed normal proliferation in the bone marrow aspirate smear but had poor sampling in the bone marrow biopsy. A clear diagnosis was finally reached on these seven cases, based on a second bone marrow aspirate smear and biopsy.
There was a severe decrease in the number of megalokaryocytes in the bone marrow aspirate smears (mean of 1 cell/slide) of 137/142 (96.5%) cases; 5/142 (3.5%) cases with 7 -12 cells/slide were all diagnosed with chronic AA.
The mean cumulative score for neutrophil alkaline phosphatase (NAP) in patients with AA was 176 (normal range 44 -82). Patients in the SAA group showed a significantly higher cumulative NAP score compared with patients in the NSAA and MDS groups (P < 0.01), while patients in the NSAA group had a significantly higher cumulative NAP score compared with patients in the hypocellular MDS group (P < 0.05).
There was a significantly lower number of CD34 + cells present in the bone marrow aspirates of patients with AA than in the bone marrow from those with hypocellular MDS (P < 0.05). The CD4/CD8 T-cell ratio in the SAA and NSAA groups was also significantly lower compared with the hypocellular MDS group (P < 0.05).
CHROMOSOME AND FISH EXAMINATIONS
The bone marrow cell culture for chromosomal examination failed in 14 cases of AA without mitosis being shown. Of the remaining 128 AA cases, three showed abnormal results in routine G-banding analysis.
One case was 46,XX,inv(10)(q11.2q22) [40] ; the inversion of the long arm of chromosome 10 was a congenital abnormality unrelated to neoplastic diseases, as indicated by chromosome examination of a phytohaemagglutinin-stimulated peripheral blood culture. One case was 46,XY,del(20)(q11.2q12) [3] /46,XY [10] ; results from two bone marrow aspirations and biopsies all confirmed that this patient (who died from infection 3 months after diagnosis) had AA. Another case was 47,XX,+8 [10] /46,XX [10] . Two of the patients with AA did not show chromosomal abnormalities on routine examinations; however, the parallel FISH examination (with 500 interphase cells) showed low-level (4% -5%) loss on chromosome 8 in their bone marrow samples. The combined results of routine chromosome analysis and FISH examination revealed that the rate of clonal chromosomal abnormalities was 3.9% (5/128) in patients with AA. In comparison, 7/22 (31.8%) patients with hypocellular MDS showed chromosomal abnormalities.
THERAPY EFFECTIVENESS RATES
Among the 75 cases of SAA, nine (12.0%) received ATG + CSA therapy, 34 (45.3%) received CSA + androgen therapy, 20 (26.7%) received androgen monotherapy and 12 (16.0%) either received traditional Chinese medicine or were untreated. The effectiveness rate of ATG + CSA was 77.8% (7/9), with six cases of CR and one case of PR. Two patients with very severe AA died of haemorrhage and infection, respectively, within 1 month of ATG treatment. The average time for therapy to take effect was 3 months (range 2 -4 months). The effectiveness rate of CSA + androgen therapy was 58.8% (20/34), with seven cases of CR and 13 cases of PR, and an average of 6 months (range 4 -10 months) for the therapy to take effect. The effectiveness rate of androgen monotherapy was 25.0% (5/20), with all five patients showing PR, and an average of 4 months (range 3 -6 months) for the therapy to take effect. W Wang, X Wang, X Xu et al.
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Among the 67 cases of NSAA, one patient received ATG + CSA therapy and CR was achieved. CSA + androgen therapy was received by 27 patients (40.0%), 32 (47.8%) received androgen monotherapy, and seven (10.4%) received traditional Chinese medicine. The effectiveness rate of CSA + androgen therapy was 81.5% (22/27), with eight cases of CR and 14 cases of PR, and an average of 5.5 months (range 3 -8 months) for the therapy to take effect. The effectiveness rate of androgen monotherapy was 46.9% (15/32), with all 15 cases showing PR and an average of 4 months (3 -6 months) for the therapy to take effect.
SURVIVAL RATES
The median survival time could not be determined from the study follow-up examinations. The 1-, 3-and 5-year survival rates were 66.7, 61.3 and 60.2%, respectively, for patients with SAA, and 89.4, 87.9 and 87.9%, respectively, for patients with NSAA (Fig. 1) . The 5-year survival rate in the ATG + CSA therapy group was 74.1%, whereas that in the CSA + androgen therapy group was 76.8% (not statistically significant) (Fig. 2 ).
PROGNOSTIC FACTORS THAT AFFECTED SURVIVAL
Multivariate analysis of prognostic factors using the Cox proportional hazards model showed that therapeutic regimen and platelet count affected the survival of patients. In patients treated with ATG + CSA therapy, those with relatively higher platelet counts had longer survival times. Age, absolute neutrophil count, haemoglobin level, bone marrow megakaryocyte number, extent of bone marrow hyperplasia and CD4/CD8 ratio did not show a significant correlation with prognosis ( Table 3 ).
Discussion
Routine blood tests and peripheral blood smears are important for the differential diagnosis of AA and MDS. Common parameters in routine blood tests (such as RDW, lymphocyte ratio and absolute reticulocyte counts) differ significantly between AA and MDS. Thus, routine blood tests can be used as screening tests for W Wang, X Wang, X Xu et al. Diagnosis and treatment of acquired aplastic anaemia differentiating these diseases. 21 Traditionally, AA is a normocytic-normochromic anaemia, whereas MDS exhibits macroerythrocytes. The present study showed that just over 73% of patients with NSAA and 20% of patients with SAA had MCV > 100 fl, compared with 55% with MDS. Thus, MCV has little significance in the differential diagnosis of AA and hypocellular MDS.
Furthermore, peripheral blood smear examinations showed a > 80% detection rate for either myeloblasts or erythroblasts in patients with hypocellular MDS, whereas no myeloblasts were seen in patients with SAA. According to the data, a diagnosis of AA could be excluded if myeloblasts are detected in peripheral blood smears.
In the diagnosis of AA, two factors that may affect judgement should be taken into account, when performing cell morphology examinations to evaluate hyperplasia of bone marrow haematopoietic tissue using W Wang, X Wang, X Xu et al. Diagnosis and treatment of acquired aplastic anaemia aspirate smears. First, bone marrow aspirate smear examinations only reveal the haematopoietic condition of bone marrow at the site of aspiration, and not the systemic haematopoietic condition of the patient. Secondly, bone marrow fluids contain sinus blood; however, as only bone marrow spicules are the real haematopoietic tissue, differential counts of cells in bone marrow spicules must be performed for AA diagnosis. Consequently, bone marrow aspirate smears without bone marrow spicules cannot be used for diagnosis, and bone marrow aspiration must be repeated. Only 54.2% of the patients in the present study were diagnosed with AA based on a single bone marrow aspiration in combination with clinical data and peripheral haemogram results, indicating that it is imprudent to make a diagnosis of AA based on a single bone marrow aspirate smear.
Dyshaematopoiesis is the major morphological characteristic of MDS. Patients with AA do not usually exhibit dyshaematopoiesis, although 4.5% of patients with NSAA in the present study displayed erythroid dyshaematopoiesis. Compared with the morphological characteristic of MDS, in which all three lines of cells can exhibit dyshaematopoiesis, the dyshaematopoiesis in patients with AA was limited to erythroid cells, with most cases showing dyshaematopoiesis in < 10% of erythroid cells. Thus, it is not difficult to distinguish AA from MDS using dyshaematopoiesis as an indicator.
Bone marrow biopsy provides a much more accurate determination of hyperplasia in haematopoietic tissue than bone marrow aspirate smears. Bone marrow biopsies in the present study indicated a decrease in the amount of haematopoietic tissue in 18 patients with AA, with normal or active proliferation in their bone marrow. The diagnosis rate of AA was up to 95% based on a single bone marrow biopsy at a single site, together with clinical, peripheral haemogram and a bone marrow aspirate smear data. This diagnostic rate was much higher than that based on bone marrow aspirate smears alone. During bone marrow biopsy, attention should be given to the quality of the sample. Biopsy tissue samples > 2 cm are usually required, to reduce experimental error. A few patients were misdiagnosed with AA during the follow-up in the present study because inadequate bone marrow haematopoietic tissue had been collected. Thus, pathological examination of bone marrow biopsy samples is a necessary procedure for AA diagnosis.
Most researchers believe that patients with clonal chromosomal abnormalities should be diagnosed with MDS rather than AA. A few patients with AA in the present study exhibited clonal chromosomal abnormalities at the initial diagnosis, at a rate of 3.9%. There were two cases of -8, one case of +8 and one case of del(20q). The chromosomal abnormality rate at initial diagnosis has been reported to range from 2% to 7% in other countries, with +8, +6 and -7 being the frequently seen abnormalities. 22 -24 When FISH analysis was used in the present study, two cases of -8 were detected. This is a lowlevel abnormality that cannot be detected by conventional chromosomal analysis. Whether the -8 chromosomal abnormality has prognostic significance is still unclear and requires further study. According to our observations, the three patients with abnormalities on chromosome 8 were still alive with a stable disease condition after 2 years of follow-up. The patient with the del(20q) died 3 months after diagnosis, indicating that abnormality on chromosome 8 may not be a predictive indicator for poor In China, there is an urgent need to standardize treatment for AA. According to clinical practice guidelines, 14 for patients with SAA who are aged < 40 years, the first-line treatment of choice is allotransplantation from a related donor with compatible human leucocyte antigen, whereas for patients with SAA who are aged ≥ 40 years the first-line treatment of choice is ATG + CSA. According to the results of a meta-analysis, ATG + CSA therapy reduces mortality by up to 50%. 15 An effectiveness rate of 74% was observed for ATG + CSA therapy 6 months after treatment, while a rate of 46% was observed for CSA therapy alone. 26 Patients on CSA alone showed fewer cases of CR (mostly PR cases). AA tends to relapse with a reduction in the dose of CSA. Thus, ATG + CSA therapy has become a standard therapy for SAA. 26, 27 Chinese medicinal herbs are not effective in the treatment of SAA and have a little effect on NSAA, although a placebo effect may occur.
None of the 75 cases with SAA included in the present study received allotransplantation; this is probably because of a lack of suitable donors or because of patients' concerns regarding the relatively high death rate during transplantation. Only 12.0% of the patients with SSA received ATG + CSA treatment, while 45.3% received CSA + androgen treatment and 26.7% received androgen monotherapy. At present, randomized, controlled trial data demonstrate that androgens are ineffective for the treatment of patients with SAA and that they are unable to improve the therapeutic effect of ATG. 18, 28 The present study indicated that treatment for AA is not standardized in Shanghai. The European Group for Blood and Bone Marrow Transplantation reported that only approximately 50% of the patients who should have received strong immunosuppressive agents actually had ATG + CSA therapy in 1999, while approximately 75% of patients received this standard therapy in 2002. 29 Compared with Western countries, AA therapeutic regimens in China require further improvement. The current imperative for AA treatment is to standardize treatment and make therapeutic decisions according to clinical practice guidelines. Because, in China, patients with AA are normally the only child in their family, relative allotransplantation donors are scarce. Thus, ATG + CSA therapy should be widely advocated and used, while CSA monotherapy should not be recommended as a first-line therapy.
The effectiveness rate of ATG + CSA therapy for SAA reached 77.8% in the present study, with a 74.1% 5-year survival rate. Similar rates have been reported in Europe and the USA, the survival rates varying between 55% and 87%. 12 This indicates that the level of AA therapy in China is comparable with that in developed countries. Furthermore, if the Chinese medical system follows clinical practice guidelines, the current therapeutic effect on SAA may be greatly improved.
Multivariate analysis in the present study revealed that therapeutic regimen and • Received for publication 10 November 2010 • Accepted subject to revision 15 February 2011
• Revised accepted 9 May 2011 Copyright © 2011 Field House Publishing LLP platelet count were the two most important prognostic factors affecting survival. This indicates that patient prognosis may be improved by closely monitoring platelet levels and actively infusing platelets to maintain a level > 20 × 10 9 /l. One of the two deaths occurring after ATG therapy was caused by haemorrhage. Thus, as long as the supporting therapy is strengthened, better therapeutic effects will be achieved.
Most clinical practice guidelines indicate that therapeutic effect can be evaluated 3 -4 months after ATG + CSA therapy, to determine if a second course of treatment with ATG is required. 30 The present study indicated that the average time for therapy to take effect was 3 months, which is consistent with other reports. 30, 31 The time varied for CSA to take effect, with an average of 6 months; in some cases it took 8 -10 months for CSA to show effects. Thus, we suggest that, for patients on CSA monotherapy, therapy should continue even if no effects are observed after 6 months of treatment. Therapeutic effect should then be re-evaluated after 12 months before ineffectiveness is confirmed and CSA monotherapy discontinued.
The present study had some limitations with regard to bias in case selection and length of follow-up time. Because of selection bias in choosing cases, patients with SAA comprised a high percentage of the total number of patients in the study cohort. Mild AA is usually diagnosed and treated at an outpatient clinic without bone marrow biopsy and chromosome examinations. The present study required that only patients who underwent complete tests could be enrolled and so patients with mild AA were largely excluded, resulting in a relatively low percentage of patients with NSAA. This does not, however, affect the conclusions regarding the therapeutic effects and prognosis of SAA. The longest follow-up time in this study was 6 years and the shortest was 2 years, which is not long enough for diseases with long survival times such as AA. For that reason, it was not possible to reach conclusions on the median survival time and the recurrence rate of AA after decreasing the CSA dosage. Because of the small number of patients on ATG therapy, the incidence rate of clonal diseases after using ATG, as well as factors that affect the therapeutic effect of ATG, could not be evaluated. Further multicentre studies, with large sample sizes, are therefore required.
